Skip to main content

Peer Review reports

From: Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML

Original Submission
27 Apr 2021 Submitted Original manuscript
19 May 2021 Reviewed Reviewer Report - Muslim Syed
24 Aug 2021 Author responded Author comments - Sonia Jaramillo
Resubmission - Version 2
24 Aug 2021 Submitted Manuscript version 2
1 Oct 2021 Editorially accepted
3 Nov 2021 Article published 10.1186/s13063-021-05703-w

You can find further information about peer review here.

Back to article page